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Abstract
Background: The mechanisms by which glucocorticoid therapy promotes obesity and insulin
resistance are incompletely characterized. Modulations of the metabolically active hormones,
tumour necrosis factor alpha (TNF alpha), ghrelin, leptin and adiponectin are all implicated in the
development of these cardiovascular risk factors. Little is known about the effects of short-term
glucocorticoid treatment on levels of these hormones.
Research methods and procedures: Using a blinded, placebo-controlled approach, we
randomised 25 healthy men (mean (SD) age: 24.2 (5.4) years) to 5 days of treatment with either
placebo or oral dexamethasone 3 mg twice daily. Fasting plasma TNFα, ghrelin, leptin and
adiponectin were measured before and after treatment.
Results:  Mean changes in all hormones were no different between treatment arms, despite
dexamethasone-related increases in body weight, blood pressure, HDL cholesterol and insulin.
Changes in calculated indices of insulin sensitivity (HOMA-S, insulin sensitivity index) were strongly
related to dexamethasone treatment (p < 0.001).
Discussion: Our data do not support a role for TNF alpha, ghrelin, leptin or adiponectin in the
insulin resistance associated with short-term glucocorticoid treatment.
Background
Glucocorticoids are common therapy for inflammatory
conditions, but they generate a diverse array of unwanted
side effects [1]. Their mechanisms of action involve the
activation of transcription factors that interact with a bat-
tery of responsive genes, stimulating inflammatory and
immuno-regulatory cross-talk [2]. Glucocorticoid therapy
promotes both insulin resistance [3,4] and central obesity
[5], perpetuating cardiovascular risk [6]. However, the
mechanisms of glucocorticoid-mediated obesity remain
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incompletely characterized, and the impact of glucocorti-
coids on hormones and cytokines that regulate hunger,
satiety and adiposity remain unclear. Therefore, we sought
to determine the acute effects of glucocorticoid adminis-
tration on tumor necrosis factor – alpha (TNF alpha),
ghrelin, leptin, and adiponectin–all hormones and
cytokines thought to play an important role in the regula-
tion of adiposity [7].
TNF alpha represents a potential link between adiposity
and insulin resistance, since circulating levels are associ-
ated with adipose mass and exogenous administration
increases insulin resistance [8]. Ghrelin, an orexigenic gut
peptide, is implicated in long- and short-term body
weight regulation. Exogenous administration blocks insu-
lin action, both via indirect effects on other hormones and
via direct actions in the liver [9]. Leptin is an adipocyte-
derived hormone that circulates in proportion to body fat
stores; it promotes weight loss and increases insulin sensi-
tivity [10]. Adiponectin, also from adipose tissue,
increases insulin sensitivity and can decrease body weight
[11]. We hypothesised that short-term glucocorticoid
treatment among healthy individuals would cause insulin
resistance, with coordinated increases in TNF alpha, leptin
and ghrelin, and decreases in adiponectin. For this study,
we used a synthetic glucocorticoid, dexamethasone,
which selectively targets the glucocorticoid receptor and
glucocorticoid responsive genes, without significant min-
eralocorticoid effects [1].
Methods
Weperformed a randomized, double-blind, placebo-con-
trolled study in healthy young men ages 19–39 who were
recruited by local advertisements. The methods are
described in detail elsewhere [12]. Briefly, subjects were
treated with dexamethasone 3 mg twice daily for 5 days or
with placebo. Fasting 8 AM blood samples were obtained
before and after the intervention. Potential subjects were
excluded if they had any of the following: ongoing medi-
cal or psychiatric illnesses, regular use of prescription or
non-prescription medications, illicit drug use or excessive
alcohol use, surgery or hospitalization in the preceding 3
months, exposure to exogenous glucocorticoids in the
preceding year, or non-traditional sleep/wake habits (e.g.:
night shift work, frequent travel across time zones). Sub-
jects were advised to maintain their usual sleep-wake
schedule, exercise and dietary habits during the study, and
were advised not to take any prescription medications,
over-the-counter medications, or alcohol during the pro-
tocol. All subjects provided written informed consent.
Investigators and subjects were blinded to treatment
assignment, and compliance was confirmed by measuring
post-treatment cortisol levels (undetectable in all subjects
who received dexamethasone). The Cleveland Clinic
Foundation Institutional Review Board approved the pro-
tocol.
Laboratory data
Separated serum and EDTA plasma were stored at -70°C
for batch analysis. Serum levels of glucose, cholesterol
and triglycerides were determined using routine autoana-
lyser assays. Insulin levels were determined using an
enzyme immunoassay (AIA NexIA, Tosoh Bioscience, S.
San Francisco, CA). TNFα, leptin and adiponectin levels
were measured by enzyme linked immunosorbant assay
(ELISA) in plasma, using commercially available antibod-
ies (R&D Systems, Abingdon, UK). Plasma ghrelin was
measured by radio-immunoassay (Phoenix Pharmaceuti-
cals, Belmont, CA).
Insulin sensitivity was assessed using the homeostatic
model (HOMA-S), which is directly related to fasting
insulin and glucose levels [13]. A weighted combination
of fasting insulin and triglycerides [14], 'insulin sensitivity
index' (ISI), was also used as surrogate a marker of insulin
sensitivity.
Power calculation and statistical analysis
We hypothesised that dexamethasone treatment would
significantly decrease HOMA-S. Based on previous data
[3,14], 12 patients would be sufficient to observe a signif-
icant (p < 0.05) decrease of at least 1.9 in HOMA-S using
a two-sided test at 80% power. The change from baseline
to post-intervention was calculated in each variable (vari-
ables with highly skewed distributions were log-trans-
formed prior to this). Data were analysed using
parametric and non-parametric tests, with ANOVA and
multiple linear and logistic regression analyses as appro-
priate (SPSS Inc., Chicago, IL). Partial correlation analysis
(two-tailed) was used to adjust the effects of treatment
arm, used for bivariate analysis among all subjects.
Results
Of the 25 male subjects (24.2 (5.4) years), 13 were rand-
omized to dexamethasone and 12 to placebo. Baseline
plasma TNFα, ghrelin, leptin and adiponectin were com-
parable among subjects in the dexamethasone and pla-
cebo groups before intervention (all P > 0.15), and these
values did not change significantly after treatment (Table
1). In contrast, there were significant increases in body-
mass index (BMI), systolic blood pressure, HDL choles-
terol, serum insulin and insulin resistance amongst sub-
jects on glucocorticoid therapy compared with those on
placebo (described elsewhere [12]). All subjects treated
with dexamethasone had undetectable post-treatment
morning cortisol levels, confirming compliance with the
intervention. Mean changes (pre-treatment value minus
post-treatment value) in TNFα, leptin and adiponectin
were not significantly correlated with changes in cardio-J
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Table 1: Plasma levels of TNF alpha, ghrelin, leptin and adiponectin among healthy male volunteers during short-term intervention with either dexamethasone or placebo.
Circulating levels of 
metabolically active hormones
Pre-treatment Post-treatment Significance of the difference between changes (pre-post), 
Placebo vs. Dexamethasone (p-value)
Placebo (n = 12) Dexamethasone
(n = 13)
Placebo
(n = 12)
Dexamethasone
(n = 13)
Insulin sensitivity (HOMA-S)* 7.55 (6.885–8.85) 8.28 (7.26–9.85) 7.07 (6.03–9.96) 5.46 (4.79–7.39) < 0.001
Insulin sensitivity index (ISI)* 1.16 (0.81–1.58) 1.35 (0.95–2.48) 0.94 (0.53–2.46) 0.38 (0.26–0.77) < 0.001
Tumor Necrosis Factor alpha 
(pg/ml)
660 (230–1580) 600 (0–1080) 620 (240– 1460) 580 (0–1080) 0.68
Ghrelin (pg/ml) 422 (239–591) 342 (285–497) 359 (265–465) 291 (188–347) 0.19
Leptin (pg/ml) 14,400 (8,400–25,600) 10,700 (4,200–19,800) 17,800 (2,700–22,600) 15,900 (4,200–30,500) 0.85
Adiponectin (ng/ml) 460 (270–1380) 810 (430–2020) 490 (390–700) 1420 (910–2120) 0.17
Median (interquartile range) are shown. A decrease in HOMA-S and ISI is indicative of a reduction in insulin sensitivity.
* Changes in insulin sensitivity in this study have been previously reported [12]Journal of Negative Results in BioMedicine 2006, 5:14 http://www.jnrbm.com/content/5/1/14
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vascular risk factors, but there was a modest association
between changes ghrelin and diastolic blood pressure (P =
0.04), after adjusting for treatment arm.
On logistic analysis, treatment (placebo vs. dexametha-
sone) was associated with change in insulin sensitivity,
and remained after individual adjustment for age, and
changes in BMI, blood pressure, and HDL cholesterol: β =
-3.39, P < 0.001 (as reported with HOMA-S [12]). Using
partial correlation analysis (adjusting for treatment arm),
associations between the change in each measured varia-
ble with changes in insulin sensitivity were investigated.
Of variables analysed (including blood pressure, BMI and
fasting metabolic indices: serum lipids, non-esterified
fatty acids, TNF alpha, adiponectin, leptin, ghrelin), only
systolic blood pressure (partial correlation coefficient: -
0.50, P = 0.01) and diastolic blood pressure (-0.48, P =
0.02) were associated with HOMA-S and ISI.
Discussion
Contrary to our hypothesis, short-term dexamethasone
treatment did not significantly change levels of TNF alpha,
ghrelin, leptin or adiponectin, despite a treatment-related
hyperinsulinaemic response [12]. The implication is that
GC-mediated insulin resistance does not result from nor
elicit major changes in these metabolically active hor-
mones. Data here pertain only to insulin resistance asso-
ciated with short-term exogenous glucocorticoid
treatment, since other etiologies of insulin resistance may
result from fundamentally different mechanisms.
Dexamethasone-induced insulin resistance remains a
complex mechanism [15] that is suggested to involve
changes in whole body free fatty acid turnover, plasma
insulin concentrations [16] and alterations in both insu-
lin signal transduction [17] and glucose transporters [18]
Both leptin and adiponectin promote catabolic energy
generating processes, such as the mobilisation of triglycer-
ides stores to promote fatty acid oxidation [19]. In line
with our earlier report of a lack of effect on fasting NEFA
levels [12], data here argue against a role of aberrant NEFA
regulation as a mechanism of glucocorticoid-induced
insulin resistance. Also, while whole body lipolysis is dif-
ferent between men and women [20] there is no gender
variation in dexamethasone induced insulin resistance
[16]. Hence, this disordered NEFA metabolism reported
with dexamethasone-induced insulin resistance may be
consequential of changes involving signal transduction
and glucose transport.
Circulating levels of TNF alpha show a coordinated
increase with obesity during the course of gestational dia-
betes [21], and at a physiological level, this adipocytokine
alters insulin signal transduction [22] and secretion [23].
Moreover, adiposity correlates with plasma levels of pro-
inflammatory cytokines such as TNF alpha and the sys-
temic acute phase protein C-reactive protein (CRP). In
this study we have already reported that dexamethasone
therapy resulted in a decrease in CRP levels [12]. Circulat-
ing CRP levels are suggested to relate to adipose derived
mediators such as leptin and TNFα, and positively corre-
late with measures of obesity in otherwise healthy adults
[24,25]. In the present analysis we found no association
between absolute levels or dexamethasone-related
changes in CRP with metabolically active hormone levels.
It is important to place our findings in the context of other
studies examining the impact of glucocorticoids on meta-
bolically active hormones and cytokines. Specifically,
some human studies suggest that glucocorticoids may
decrease ghrelin levels [26] and increase leptin levels [27].
However, one group reported that fasting obliterated the
increase in leptin in response to exogenous glucocorti-
coids [28] which may account for the lack of a rise in lep-
tin concentrations with glucocorticoid treatment in our
subjects. In longer-term studies, the impact of glucocorti-
coids on metabolically active cytokines and hormones
may be mediated by changes that accompany more
chronic glucocorticoid effects, such as obesity [29], rather
than by direct glucocorticoid effects. While it is conceiva-
ble that a larger sample size, longer treatment duration, or
non-fasting blood assays might have generated positive
findings, the highly significant change in insulin sensitiv-
ity we observed with dexamethasone reassures us that our
study design allowed for detection of major alterations in
metabolic cytokines and hormones. Furthermore, the
since all subjects who received dexamethasone had unde-
tectable post-treatment cortisol levels, we know that our
negative findings were not a result of noncompliance with
the intervention. Based on these factors, we suspect that
any effects of short-term glucocorticoids on circulating
levels of metabolic cytokines and adipokines are likely
small, if indeed present at all.
In summary, this randomised placebo-controlled study
provides insight into the effects of glucocorticoids, with-
out interference from pathological disease states that are
commonly manifest amongst patients on GC therapy.
Short-term dexamethasone therapy did not significantly
change circulating concentrations of metabolically active
hormones, despite increasing insulin resistance.
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